Bottom line
SHSAX vs QAAGZX: the short answer
SHSAX (Blackrock Health Sciences Opportunities Portfolio) and QAAGZX (T. Rowe Price Health Sciences Portfolio) are both mutual funds.
QAAGZX is cheaper at 0.86% vs 1.11% — a difference of $25 a year per $10,000 invested.
Over five years, SHSAX returned +4.5% a year vs +4.1% for QAAGZX.
SHSAX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
SHSAX vs QAAGZX side by side
| SHSAX | QAAGZX | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | BlackRock | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.11% | 0.86% |
| Annual cost per $10k | $111 | $86 |
| 10-yr cost on $10k (prospectus) | $1,806 | $1,061 |
| Max front load | 5.25% | None |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | +9.9% | +18.1% |
| 5-yr return (annualized) | +4.5% | +4.1% |
| 10-yr return (annualized) | +9.0% | +9.0% |
| Best quarter | +17.5% | +23.4% |
| Worst quarter | −11.5% | −15.8% |
| Net assets (fund) | $5.9B | $751.7M |
| Number of holdings | 155 | 277 |
| Portfolio turnover | 49% | 65% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SHSAX | QAAGZX | Difference |
|---|---|---|---|
| 2025 | +16.0% | +18.1% | −2.1% |
| 2024 | +3.9% | +1.7% | +2.2% |
| 2023 | +3.6% | +3.0% | +0.6% |
| 2022 | −5.9% | −12.5% | +6.6% |
| 2021 | +11.8% | +13.1% | −1.3% |
| 2020 | +19.5% | +29.6% | −10.2% |
| 2019 | +25.3% | +29.0% | −3.7% |
| 2018 | +8.0% | +1.1% | +6.9% |
| 2017 | +24.8% | +27.6% | −2.8% |
| 2016 | −6.1% | −10.5% | +4.4% |
Source: Fund prospectus bar charts
Holdings overlap
14 of SHSAX's top 25 holdings also appear in QAAGZX's top 25.
| Holding | SHSAX | QAAGZX |
|---|---|---|
| Eli Lilly & Company | 12.29% | 14.06% |
| Johnson & Johnson | 8.77% | 6.64% |
| Unitedhealth Group Inc | 6.10% | 5.88% |
| Merck & Company Inc | 4.94% | 4.00% |
| Gilead Sciences Inc | 4.19% | 2.79% |
| Abbvie Inc | 3.94% | 5.12% |
| Amgen Inc | 3.37% | 1.80% |
| Thermo Fisher Scientific Inc | 3.02% | 2.53% |
| Vertex Pharmaceuticals Inc | 2.74% | 2.26% |
| Danaher Corp | 2.00% | 1.44% |
| Abbott Laboratories | 1.97% | 1.91% |
| Intuitive Surgical Inc | 1.95% | 1.89% |
| Elevance Health Inc | 1.56% | 1.54% |
| Stryker Corp | 1.15% | 1.78% |
Source: SEC Form N-PORT
SHSAX top 10
- Eli Lilly & Company — 12.29%
- Johnson & Johnson — 8.77%
- Unitedhealth Group Inc — 6.10%
- Merck & Company Inc — 4.94%
- Gilead Sciences Inc — 4.19%
- Abbvie Inc — 3.94%
- Amgen Inc — 3.37%
- Thermo Fisher Scientific Inc — 3.02%
- Vertex Pharmaceuticals Inc — 2.74%
- Pfizer Inc — 2.61%
QAAGZX top 10
- Eli Lilly & Co — 14.06%
- Johnson & Johnson — 6.64%
- Unitedhealth Group Inc — 5.88%
- Abbvie Inc — 5.12%
- Merck & Co. Inc. — 4.00%
- Gilead Sciences Inc — 2.79%
- Thermo Fisher Scientific Inc — 2.53%
- Vertex Pharmaceuticals Inc — 2.26%
- Bristol-myers Squibb Co — 2.12%
- Abbott Laboratories — 1.91%
FAQ
What is the difference between SHSAX and QAAGZX?
Which is cheaper, SHSAX or QAAGZX?
Should I own both SHSAX and QAAGZX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.